COMETE Study: Comorbidity Mircera Evolution of Hemoglobin Rate; A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: December 19, 2012
Last updated: August 1, 2016
Last verified: August 2016
This prospective, multicenter, observational study will evaluate the impact of comorbidity factors on the hemoglobin level in patients with chronic kidney disease not on dialysis who are initiated on treatment with Mircera (methoxy polyethylene glycol-epoetin beta). Data will be collected from patients for 9 months after initiation of Mircera treatment.

Kidney Disease, Chronic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Non Interventional Study to Assess the Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CDK) Patients Not in Dialysis Treated With Mircera

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Proportion of patients with an increase in hemoglobin level of >/= 1g/dL or a hemoglobin level between 10 and 12 g/dL after 9 months of treatment without any transfusional recourse (total population and comorbidity subgroups) [ Time Frame: approximately 9 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical/demographic patient characteristics at initiation of treatment [ Time Frame: approximately 9 months ] [ Designated as safety issue: No ]
  • Hemoglobin levels according to Liu Index and resistance factors [ Time Frame: approximately 9 months ] [ Designated as safety issue: No ]
  • Mircera dosage [ Time Frame: approximately 9 months ] [ Designated as safety issue: No ]
  • Safety: Incidence of adverse events [ Time Frame: approximately 9 months ] [ Designated as safety issue: No ]

Enrollment: 551
Study Start Date: November 2012
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with chronic kidney disease not on dialysis and ESA naïve

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Patients with chronic kidney disease not on dialysis
  • Treatment-naïve for ESAs (not having received ESAs in the 6 months prior to inclusion in this study)
  • Hemoglobin level < 10 g/dL at inclusion
  • Patients for whom the treating physician has decided to initiate treatment with Mircera for medical reasons prior to study start

Exclusion Criteria:

  • Functional renal transplant
  • Current participation in a clinical trial in anemia due to chronic kidney disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01756612

  Show 105 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01756612     History of Changes
Other Study ID Numbers: ML28145 
Study First Received: December 19, 2012
Last Updated: August 1, 2016
Health Authority: France: Ministry of Health

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Chronic Disease
Urologic Diseases
Renal Insufficiency
Disease Attributes
Pathologic Processes processed this record on August 24, 2016